Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study

BACKGROUND: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proportions of patients treated with first- to third-line chemotherapy and to find infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Seigo, Ogata, Yoshitaka, Ihara, Shouichi, Yamamoto, Suguru, Komuta, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342614/
https://www.ncbi.nlm.nih.gov/pubmed/28293125
http://dx.doi.org/10.2147/LCTT.S124301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342614/
https://www.ncbi.nlm.nih.gov/pubmed/28293125
http://dx.doi.org/10.2147/LCTT.S124301

Ejemplares similares